Kornimate/medical-research-clean huggingface dataset:
mesh stents study in iliac complex lesions (ims-study)

Conditions: Peripheral Arterial Disease; Iliac Artery Stenosis; Embolus Arterial; Ischemic Leg

Summary: the main objective of the ims-study is to evaluate the short and long-term safety and efficacy of mesh stent implantation in patients with stenotic iliac disease with complex plaques or lesions containing thrombotic material.

iliac artery disease may include complex lesions with a vulnerable plaque and containing thrombotic materials. the treatment of these complex plaques is frequently complicated with local, acute occlusion, dissection and distal embolisation. studies with a mesh stent in the carotid region have shown a reduced risk of peripheral embolization. the use of mesh stents in iliac arteries can provide similar benefits. the structure of the stents, sizes, and the release system do not require any changes. the study is to assess the usefulness of mesh stents in preventing peripheral embolisation.

Eligibility criteria:
inclusion criteria: * general inclusion criteria (principal): * patients older than 18 years, after vascular team evaluation, according to local standards, eligible for iliac artery * written, informed consent to participate * agreement to attend protocol required (standard) follow up visits and examinations * angiographic inclusion criteria (principal): * de novo iliac stenosis * stenosis eligible for endovascular treatment per vascular team evaluation (according to current standards and guidelines) * high-risk morphology stenosis with complex/thrombotic lesions (per 1 independent, experienced operator). exclusion criteria: * general exclusion criteria (principal): * life expectancy \<1 year (e.g., active neoplastic disease). * chronic kidney disease with creatinine \> 3.0 mg/dl. * coagulopathy. * contraindication for decoagulation * history of uncontrolled contrast media intolerance * myocardial infarction in 72 hours preceding the stenting procedure (if possible, postponing the procedure) * stroke in 6 weeks preceding the stenting procedure (if possible, postponing the procedure) * pregnancy (positive pregnancy test) * angiographicexclusion criteria (principal): * chronic total occlusion not amenable to re-canalization * stent in the target vessel/lesion * anatomic variants precluding stent implantation * mobile (free-floating) plaque elements in aorta or arteries proximal to the target lesion

Keywords: iliac artery stenosis high-risk plague mesh stent peripheral embolisation peripheral arterial disease
fluid status and body composition analysis by bioelectrical impedance in patients after cardiac surgery (flubiacs)

Conditions: Cardiopulmonary Disease; Fluid Overload

Summary: evaluation of fluid status in cardiac surgery patients using bioelectrical impedance and its impact on postoperative morbidity and mortality

hydration and fluid balance dynamics after cardiac surgery is complex and requires comprehensive knowledge of bluid balance dynamics. surgical trauma, anaesthesia and use of cardiopulmonary bypass significantly influence postoperative fluid status. deviations from normal values on the other hand can be related to increase in morbidity and mortality. the purpose of this prospective observational clinical study is to assess fluid status using bioelectric impedance in patients undergoing cardiac surgery and to evaluate its impact on postoperative morbidity and mortality.

Eligibility criteria:
inclusion criteria 1. elective cardiovascular surgery (on-pump or off-pump) 2. age ≥ 18 years 3. asa 3 or 4 4. provided verbal and written informed consent exclusion criteria 1. refusal to participate in the research 2. \< 18 years 3. renal failure requiring replacement treatment with hemodialysis 4. amputation of a limb 5. pregnancy 6. emergency procedures 7. reoperation 8. pacemaker/implantable cardioverter-defibrillator
the role and mechanism of immune regulation in acute lung injury in children

Conditions: Acute Lung Injury

Summary: acute lung injury is a highly prevalent disease in children, posing a serious threat to their health and causing economic burden on society and families. it has received high attention. blocking the cascade immune inflammatory response that occurs in the respiratory tract and finding key targets for the prevention and treatment of acute lung injury has become an important challenge faced by the medical community. the pathogenesis of acute lung injury is complex, involving the combined action of multiple cells and cytokines in the immune system. therefore, it is necessary to further study the function of immune cells and specific immune pathogenesis, providing new ideas and theoretical basis for clinical treatment of acute lung injury. the omics technology includes genomics, transcriptome, proteomics, metabolomics, etc. through qualitative and quantitative analysis of changes in low molecular weight molecules or metabolites of biological samples, it provides a new way to find biomarkers and pathogenesis. we plan to study the peripheral blood of children with acute lung injury and healthy children, and use network analysis to screen for differential genes and related enrichment pathways in acute lung injury. we aim to explore the correlation between immune regulation and inflammatory repair in children with acute lung injury, and analyze the regulatory mechanisms between immune cells related to it. provide assistance for clinical diagnosis and treatment.

1. inclusion criteria of the test group: (1) meeting the specific diagnostic criteria for related lung diseases; (2) the factors of lung diseases were infection and sepsis; 2. inclusion criteria of the control group: control 1: (1) meeting the specific diagnostic criteria for related lung diseases; (2) the factors of lung diseases were non-infectious factors. control 2: healthy children 3. exclusion criteria of the test group: (1) patients with hemodynamic instability patients with pulmonary hypertension;(2) patients with congenital heart disease, congenital genetic metabolic disease, epilepsy, acute and chronic renal insufficiency, nephrotic syndrome, diabetes, et al. 4. the collection of clinical data includes: name, sex, age, hospitalization number, date of hospitalization, main diagnosis, course of disease, main examination and test results, medication, respiratory support, prognosis, etc. 5. collect peripheral blood serum, sputum or alveolar lavage fluid samples for target sequencing.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of ali/ards. * voluntary inclusion of researchers. exclusion criteria: * patients with hemodynamic instability * patients with pulmonary hypertension * patients with congenital heart disease, congenital genetic metabolic disease, epilepsy, acute and chronic renal insufficiency, nephrotic syndrome, diabetes, etc.
vaccine therapy in treating patients with metastatic melanoma of the eye

Conditions: Extraocular Extension Melanoma; Recurrent Intraocular Melanoma

Summary: rationale: vaccines may make the body build an immune response to kill tumor cells. combining vaccine therapy with interleukin-2 may be a more effective treatment for metastatic melanoma of the eye. purpose: phase ii trial to study the effectiveness of vaccine therapy and interleukin-2 in treating patients who have metastatic melanoma of the eye.

objectives: i. determine the clinical response in patients with metastatic ocular melanoma treated with gp100:209-217 (210m) antigen and mart-1:26-35 (27l) antigen emulsified in montanide isa-51. ii. determine the clinical benefit of interleukin-2 in combination with this vaccine in these patients. protocol outline: patients receive vaccine subcutaneously once weekly. treatment repeats every 4 weeks for a total of 6 courses in the absence of disease progression or unacceptable toxicity. patients with progressive disease may receive vaccine sc on day 1 followed by interleukin-2 iv over 15 minutes every 8 hours for a maximum of 12 doses. treatment repeats every 3 weeks for at least 4 courses in the absence of disease progression or unacceptable toxicity. projected accrual: a total of 15-25 patients will be accrued for this study within 1 year.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- diagnosis of metastatic ocular melanoma progressive disease measurable disease hla-a\*201 positive --prior/concurrent therapy-- biologic therapy: at least 3 weeks since prior biologic therapy chemotherapy: at least 3 weeks since prior chemotherapy endocrine therapy: at least 3 weeks since prior endocrine therapy no concurrent steroid therapy radiotherapy: at least 3 weeks since prior radiotherapy surgery: not specified --patient characteristics-- age: 16 and over performance status: ecog 0-2 life expectancy: more than 3 months hematopoietic: wbc at least 3,000/mm3 platelet count at least 90,000/mm3 no coagulation disorders hepatic: bilirubin no greater than 2.0 mg/dl ast/alt less than 3 times normal hepatitis b surface antigen negative renal: creatinine no greater than 2.0 mg/dl cardiovascular: no major cardiovascular illness for interleukin-2 (il-2) therapy: no cardiac ischemia no myocardial infarction no cardiac arrhythmias pulmonary: no major respiratory system illness for il-2 therapy: no obstructive or restrictive pulmonary disease other: not pregnant or nursing negative pregnancy test fertile patients must use effective contraception no active systemic infection no autoimmune disease no primary or secondary immunodeficiency by abnormal lymphocyte counts or presence of opportunistic infection

Keywords: adult solid tumor body system/site cancer cancer extraocular extension melanoma eye cancer intraocular melanoma recurrent intraocular melanoma solid tumor stage, intraocular melanoma
effect of "sekanjabin e safarjali" (quince oxymel) in the prevention of migraine attacks

Conditions: Migraine Headache; Gastric Diseases

Summary: the purpose of this study is to determine whether quince oxymel is effective in the prevention of migraine attacks in patients with simultaneous upper gastrointestinal dysfunction.

this is a randomized, placebo-controlled, triple blinded clinical study to evaluate the effects of oral use of "sekanjebin e safarjali" (quince oxymel) in the prevention of migraine attacks in patients with simultaneous upper gastrointestinal dysfunction.45 patients with migraine headache aged between 15-70, after taking signed informed consent, according to the international headache society criteria for headache \[2\] are included in this trial. 45 cases with migraine headache with simultaneous upper gastrointestinal dysfunction will allocate to three arms by using simple randomization. quince oxymel, propranolol and placebo will be given as encoded, innominate bottles with the same shape and color. quince oxymel and placebo will be prescribed as 10 cc, three times a day for 4 weeks. frequency, duration and intensity of migraine attacks at the beginning time and during 4 weeks of trial, will be evaluated, as the primary outcome measures.

Eligibility criteria:
inclusion criteria: * minimum age of 18 years old * giving a written informed consent * having at least 2 migraine attacks per month exclusion criteria: * patients older than 70 years old * patients with diabetes mellitus * patients with chronic obstructive pulmonary disease and asthma * pregnancy * severe depression * patients affected by sexual disorders * bradyarrhythmic patients * positive history of hypersensitivity reactions to quince, ginger, propranolol or naproxen
pharmacogenomic study to predict antidepressant responsiveness in depressed patients

Conditions: Depression; Adverse Reaction to Drug

Summary: the purpose of this study is to determine whether pharmacogenomic study predict antidepressant responsiveness in advance before the appearance of the drug effects until 4\~6 weeks after drug administration.

the purpose of this study is 1. to determine whether genomic effects on antidepressant response differed by class of drug, 2. whether genomic differences between drug responders and nonresponders predict the response of antidepressant and 3. to construct the prediction model for antidepressant treatment in order to aid to select the their genetically matching drugs.

Eligibility criteria:
inclusion criteria: 1. eligible patients were enrolled in the clinical trials program of hte samsung medical center geropsychiatry and affective disorder clinics(seoul, korea). they received a semistructured diagnostic interview, the samsung psychiatric evaluation schedule. the affective disorder section of the samsung psychiatric evaluation schedule uses the korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, fourth edition. 2. interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians exclusion criteria: 1. received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks 2. potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant axis i psychiatric disorder.

Keywords: pharmacogenomics prediction of antidepressant response depressed patients
dexmedetomidine reduces emergence delirium in children undergoing tonsillectomy with propofol anesthesia

Conditions: Emergence Delirium; Extubation Time; Heart Rate; Postoperative Analgesia; Blood Pressure

Summary: dexmedetomidine (dex) is safe and effective in reducing ed following sevoflurane anesthesia. the investigators intend to study the efficacy of dex in reducing ed in children undergoing tonsillectomy with and without adenoidectomy using total intravenous anesthesia (tiva) with propofol .


Eligibility criteria:
inclusion criteria: * children * asa i or ii * tonsillectomy with or without adenoidectomy exclusion criteria: * allergy to dexmedetomidine * allergy to anesthetic drugs * history of neurological disease * history of neuromuscular disease * history of renal disease * history of hepatic disease * craniofacial anomalies * history of cardiac disease * history of respiratory disease

Keywords: dexmedetomidine emergence delirium anesthesia propofol children
orlistat reduces uric acid in overweight/obese patients with hyperuricemia

Conditions: Uric Acid

Summary: to clarify the uric acid-lowering efficacy of orlistat in overweight/obese patients with hyperuricemia, and to evaluate the safety of orlistat treatment


Eligibility criteria:
inclusion criteria: (items 1, 2, and 4 meet at the same time, and items 3 and 5 meet one of them) 1. obtain the informed consent of the subjects before any trial-related activities (including activities carried out to assess the eligibility of subjects); 2. men or women over the age of 18 at the time of screening; 3. the diagnosis of hyperuricemia refers to the fasting of serum uric acid \> 420umol/l (7 mg/dl) twice on different days under a normal purine diet. 4. the weight meets the following requirements (a or b): a) bmi ≥ 25.0 kg/m2; b) waist circumference, female ≥ 85 cm, male ≥ 90 cm. 5. suffering from hyperuricemia and/or gout.- exclusion criteria: 1. use of drugs that may affect uric acid within 1 month before enrollment, including; benzbromarone, allopurinol, febuxostat, etc.; 2. abnormal liver function, alt and ast are more than 2.5 times the upper limit of normal; 3. other diseases that affect glucose and lipid metabolism: hyperthyroidism, hypothyroidism, hypercortisolism, etc.; 4. diabetic patients with poor blood sugar control: hba1c\>7%; 5. chronic kidney disease or severe renal impairment, according to egfr grading \<45ml/min/1.73m2; 6. the life expectancy does not exceed 5 years; 7. female subjects who are pregnant or plan to become pregnant within the next 24 weeks; 8. those who are expected to be unable to complete the intervention follow-up in other circumstances; 9. if other drugs are used in combination, the drug dose should be kept stable for three months before enrollment; 10. participated in other clinical trials within the past 4 weeks; 11. use of drugs that affect body weight within 3 months before screening, including: systemic steroids (intravenous, oral or intra-articular), tricyclic antidepressants, psychiatric drugs or sedatives (eg, imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salt), etc.; 12. obesity caused by secondary diseases or drugs, including: elevated cortisol hormone (for example: cushing's syndrome), obesity caused by pituitary and hypothalamus damage, obesity caused by reduction/discontinuation of weight loss drugs, etc.; 13. inability to complete the exercise and for other reasons, the researcher believes that it is not suitable to participate in this researcher.-
the response to intralesional il-2 and/or bcg treatment for cutaneous metastatic melanoma

Conditions: Cutaneous Metastatic Melanoma

Summary: the investigators aim to include 100 local participants over the next 5 years in a two-stage sequential randomized interventional study of intralesional interleukin-2 (il-2) and bacillus calmette guerin (bcg) to assess the utility of treating cutaneous metastatic melanoma (cmm).

in the first stage of the study, all consenting cmm patients will be randomized and will receive 4 treatments of either intralesional il-2 or intralesional il-2 and bcg. we hypothesize that patients with mm (stage 3c or 4a with a minimum of 4 lesions) that receive combination therapy (il-2/bcg) in the first stage of treatment will have a higher complete response (icr) rate compared to il-2 therapy alone. response to stage-one treatment will be monitored and patient response to treatment will be determined and reported according to immune response evaluation criteria in solid tumours (irecist) guidelines. based on response to stage-one treatment, patients will be placed into a response group before entering stage two. for stage two of the trial, patients will be randomized again, and placed into a treatment group; il-2, il-2 and bcg, bcg, or discontinue treatment. response to treatment will be monitored and patient response to treatment will be determined and reported according to irecist guidelines. all patients will have lesions biopsied following standard surgical practice techniques and will provide urine and blood for analysis. tissue samples will be assessed for immune system activity and transcriptome analysis, and urine and blood will be assessed for immune cell populations and markers. all patients will be followed for 5 years post treatment, and patient disease and survival status will be recorded according to irecist.

Eligibility criteria:
inclusion criteria: * patient with cutaneous metastatic melanoma. * has 4 or more melanoma lesions. * between18 and 80 years of age. exclusion criteria: * immunocompromized. * receiving immuno-therapy for other diagnosis. * inflammatory disease. * autoimmune disease. * pregnant * hiv * test positive for tb

Keywords: interleukin-2 bacillus calmette guerin
implementing acupuncture and chinese herbal medicine into palliative care

Conditions: Advanced Cancer; Lung Cancer; Breast Cancer; Colo-rectal Cancer; Pancreas Cancer; Cholangiocarcinoma; Quality of Life; Symptoms and Signs

Summary: in this clinical trial we want to investigate the clinical benefit of a complementary therapy using therapeutical modalities of the traditional chinese medicine in patients suffering from advanced cancer.

after giving informed consent, the participants will be randomized into two groups (1:1). both groups will receive standard care while one group will additionally be assigned to a practitioner of traditional chinese medicine (tcm) who will deliver a individual treatment according to the needs of the participant (pragmatic approach). outcome measures will be monitored over the course of eight weeks.

Eligibility criteria:
inclusion criteria: * one of the following tumor entities * colorectal cancer (crc) * lung cancer (sclc, nsclc) * breast cancer (bc) * pancreas/cholangiocellular cancer * best supportive care (i.e., no currently ongoing tumor-specific therapy) o exception: palliative anti-hormonal therapy or palliative radiotherapy * performance status: ecog 0 to 2 * estimated life expectancy \> 4 months exclusion criteria: * any serious concomitant systemic disorder * pregnancy or breast-feeding * impossibility to attend tcm practices in graz * incapacity to comply/consent * language barrier * brain metastases

Keywords: palliative care traditional chinese medicine acupuncture chinese herbal medicine
efficacy of neuromuscular electrical stimulation in geriatric population

Conditions: Age-Related Atrophy; Physical Disorder

Summary: the decline in physical function and strength was seen by the nature of aging. the older adults often complain of fatigue. for these reasons, proper rehabilitation approaches should be used to ensure healthy life and to keep the quality of life at the highest possible level by minimizing the decline seen with aging process. exercise programs and neuromuscular electrical stimulation (nmes) are applied in rehabilitation to restore muscular strength and improve physical performance. nmes is used to prevent the atrophy of nonuse, to increase joint range of motion, to re-educate muscle, to regulate spasticity, to replace orthosis, to improve motor involvement of muscle fibers. despite the use of nmes for strengthening in the clinics, the application parameters and methods should be discussed. the frequency, the pulse duration, the on / off time, the amplitude, the waveform of the current and the application time vary between the studies. for geriatric populations, it is recommended that the highest intensity, biphasic symmetrical currents with a frequency in the range of 50-100 hz, for 100-400 μs, can be pulsed for ideal amplification. nmes is usually practiced by physiotherapists continuously for 20 minutes in to strengthen. however, in recent studies, it has been shown that continuous application of a single-session 100 hz current for 20 minutes leads to intense fatigue and after a while the effect of the strengthening of the current has been removed. therefore, intermittent applications have been proposed instead of continuous applications for 20 minutes. considering the fragility and the presence of sarcopenia in the geriatric population, nmes applications should be preferred in which rest periods are given instead of continuous application for 20 minutes. in the literature, there is no study showing the effect of nmes on quadriceps strength, fatigue and physical function by using quadriceps stimulation for 20 minutes using different stimulation periods.therefore, in this study, will be investigated the possible effects of two different methods of nmes on quadriceps strength, fatigue and physical function.


Eligibility criteria:
inclusion criteria includes * age 60 years or older * be able to climb one floor of stairs independently * not participate in an exercise program to increase strength or physiotherapy programme. exclusion criteria: * having a medical condition in which nmes training is contraindicated * having a cognitive impairment * having implanted cardiac pacemaker

Keywords: neuromuscular electrical stimulation geriatric population physical function quadriceps fatigue